Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AN2 Therapeutics Inc | ANTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.99 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.99 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.92 - 22.22 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.99 | USD |
AN2 Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 60.08M | 29.74M | - | 0 | -64.73M | -2.18 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AN2 Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.05 | 2.13 | 1.9416 | 2.00 | 452,268 | -0.06 | -2.93% |
| 1 Month | 2.60 | 2.64 | 1.92 | 2.13 | 184,334 | -0.61 | -23.46% |
| 3 Months | 2.91 | 3.88 | 1.92 | 2.85 | 291,134 | -0.92 | -31.62% |
| 6 Months | 17.00 | 22.22 | 1.92 | 5.58 | 319,007 | -15.01 | -88.29% |
| 1 Year | 6.26 | 22.22 | 1.92 | 6.74 | 199,537 | -4.27 | -68.21% |
| 3 Years | 16.85 | 23.58 | 1.92 | 8.03 | 118,631 | -14.86 | -88.19% |
| 5 Years | 16.85 | 23.58 | 1.92 | 8.03 | 118,631 | -14.86 | -88.19% |
AN2 Therapeutics Description
| AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. |
